Squib

Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Friday, June 4, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Bristol Myers Squibb, Life sciences, Companies, Squib, Industry economics)

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, June 10, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, June 10, 2021.
  • Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development , will answer questions about the company at 9:40 a.m.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases

Retrieved on: 
Wednesday, June 2, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Companies, Life sciences, Bristol-Myers Squibb, Biotechnology companies, Celgene, Summit, New Jersey, Bristol Myers Squibb, Juno Therapeutics, Squib

Bristol Myers Squibb (NYSE:BMY) today announced that data from 28 company-sponsored and investigator-sponsored studies will be presented at the EULAR 2021 Virtual Congress taking place June 2-5, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced that data from 28 company-sponsored and investigator-sponsored studies will be presented at the EULAR 2021 Virtual Congress taking place June 2-5, 2021.
  • Bristol Myers Squibb-sponsored abstracts that will be presented at EULAR 2021 can be found below.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
  • In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights

Retrieved on: 
Tuesday, May 25, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Fitness & Nutrition, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Bristol Myers Squibb, Companies, Life sciences, Squib, Monoclonal antibodies, Industry economics), Bristol-Myers Squibb

Bristol Myers Squibb (NYSE: BMY) today announced that the company will host a virtual Investor Event on Tuesday, June 8, 2021 at 1 p.m.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will host a virtual Investor Event on Tuesday, June 8, 2021 at 1 p.m.
  • ET to discuss data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Bristol-Myers Squibb Company’s Directors and Officers for Breach of Fiduciary Duties – BMY

Retrieved on: 
Thursday, May 20, 2021
Bristol Myers Squibb, Squib, Myers, Companies, Life sciences, Industry economics)

b'NEW YORK, May 20, 2021 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (\xe2\x80\x9cScott+Scott\xe2\x80\x9d), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Bristol-Myers Squibb Company (\xe2\x80\x9cBristol-Myers\xe2\x80\x9d) (NYSE: BMY) for breaching their fiduciary duties to Bristol-Myers and its shareholders.

Key Points: 
  • b'NEW YORK, May 20, 2021 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (\xe2\x80\x9cScott+Scott\xe2\x80\x9d), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Bristol-Myers Squibb Company (\xe2\x80\x9cBristol-Myers\xe2\x80\x9d) (NYSE: BMY) for breaching their fiduciary duties to Bristol-Myers and its shareholders.
  • On April 1, 2021, the New York Times reported that the I.R.S.
  • believes that Bristol-Myers used an abusive offshore scheme to avoid federal taxes in excess of $1 billion.\nIf you are a Bristol-Myers shareholder, you may have legal claims against Bristol-Myers\xe2\x80\x99s directors and officers.
  • The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.\n'

Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Bristol Myers Squibb, Squib, Companies, Life sciences, Monoclonal antibodies, Biotechnology

b'Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021.

Key Points: 
  • b'Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021.
  • Dr. Hidalgo will serve as a member of the Science & Technology Committee of the Board of Directors.\nThis press release features multimedia.
  • For more information about the Bristol Myers Squibb Board of Directors, click here .\nBristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .\n'

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

Retrieved on: 
Wednesday, May 19, 2021
Technology, Mobile, Wireless, Clinical trials, Software, Biotechnology, Internet, Health, Pharmaceutical, Data management, Bristol-Myers Squibb, Life sciences, Companies, Bristol Myers Squibb, Industry economics), Celgene, Squib, Monoclonal antibodies

This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia\xe2\x80\x99s portfolio of shared assets.

Key Points: 
  • This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia\xe2\x80\x99s portfolio of shared assets.
  • Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.\nThis expanded collaboration builds upon Exscientia\xe2\x80\x99s existing collaboration with Bristol Myers Squibb that was initiated in 2019 with Celgene prior to Celgene\xe2\x80\x99s acquisition by Bristol Myers Squibb.
  • Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with this collaboration for Bristol Myers Squibb.
  • We\xe2\x80\x99re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients.\xe2\x80\x9d\nRupert Vessey, President of Research & Early Development at Bristol Myers Squibb said, \xe2\x80\x9cWe have been pleased with Exscientia\xe2\x80\x99s work in tackling a number of distinct projects for Bristol Myers Squibb.

Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring

Retrieved on: 
Wednesday, May 19, 2021
Health, Clinical trials, Medical devices, Human–computer interaction, Distributed computing architecture, Bristol-Myers Squibb, Bristol Myers Squibb, Squib, BMS, Wearable technology, Life sciences

b"Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb (BMS, NYSE: BMY) will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients\xe2\x80\x99 infusion with the cell therapy.

Key Points: 
  • b"Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb (BMS, NYSE: BMY) will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients\xe2\x80\x99 infusion with the cell therapy.
  • This observational trial will be Bristol Myers Squibb\xe2\x80\x99s first use of a remote patient monitoring technology to track CAR T patient temperatures, which can be a sign of cytokine release syndrome (CRS), a common side effect observed within the CAR T category of therapies.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210519005124/en/\nBlue Spark Technologies' TempTraq\xc2\xae Wearable Wireless Thermometer (Photo: Business Wire)\nIn the partnership, Blue Spark Technologies will supply the TempTraq wearable device for use by patients with multiple myeloma or lymphoma who are participating in the observational trial to receive a Bristol Myers Squibb CAR T product.
  • It can also directly integrate with healthcare provider electronic medical record (EMR) systems and nurse monitoring stations, providing a secure method of storing patient healthcare data.

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

Retrieved on: 
Tuesday, May 18, 2021
Agenus, Companies, Bristol Myers Squibb, Squib, Life sciences, Biotechnology companies

b'NEW YORK and LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company\xc2\xa0(NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus\xe2\x80\x99 proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.

Key Points: 
  • b'NEW YORK and LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company\xc2\xa0(NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus\xe2\x80\x99 proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
  • AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
  • Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US.
  • \xe2\x80\x9cWe look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.\xe2\x80\x9d\n\xe2\x80\x9cWe are pleased to partner with Bristol Myers Squibb to develop and commercialize AGEN1777.

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, General Health, Pharmaceutical, Health, Agenus, Companies, Bristol Myers Squibb, TIGIT, Squib, Life sciences, Biology

b'Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus\xe2\x80\x99 proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.

Key Points: 
  • b'Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus\xe2\x80\x99 proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
  • AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
  • Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US.
  • \xe2\x80\x9cWe look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.\xe2\x80\x9d\n\xe2\x80\x9cWe are pleased to partner with Bristol Myers Squibb to develop and commercialize AGEN1777.

Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious diseases, Genetics, Other Health, Companies, Finance, Bristol Myers Squibb, Banks, Squib, Myers, UBS

b'Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the UBS Global Healthcare Virtual Conference, which will be webcast on Tuesday, May 25, 2021.

Key Points: 
  • b'Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the UBS Global Healthcare Virtual Conference, which will be webcast on Tuesday, May 25, 2021.
  • David Elkins, Executive Vice President, Chief Financial Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development , will answer questions about the company at 1 p.m. ET.\nInvestors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com .
  • An archived edition of the session will be available later that day.\nBristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .\n'